Medication info
Janumet XR Tablet 50/500 mg

Janumet XR Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
HLB Bio Co., Ltd.
Appearance
Bright blue, oval-shaped extended-release film-coated tablets that are convex on both sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202071 · Approved 2022.05.17 · Insurance code 647304390

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole; do not split, crush, grind, or chew it. Cases of incomplete dissolution of this drug and excretion in the feces have been reported. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of drug treatment for diabetes who have difficulty achieving adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used). 2. Patients receiving metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used).

Ingredients

Manufacturer
HLB Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar in patients with type 2 diabetes. It assists in managing blood sugar more effectively when combined with diet and exercise therapy. The combination of sitagliptin and metformin helps regulate blood sugar levels and alleviate diabetes symptoms. Therefore, this medication is used to enhance blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole; do not split, crush, grind, or chew it. Cases of incomplete dissolution of this drug and excretion in the feces have been reported. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of drug treatment for diabetes who have difficulty achieving adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used). 2. Patients receiving metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used).

Precautions

This medication contains sitagliptin and metformin and is used in the treatment of diabetes. First, when taking this medication, allergic reactions may occur, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a doctor. Additionally, this medication can cause serious pancreatic illness known as pancreatitis, so if abdominal pain, nausea, vomiting, sudden weight loss, or jaundice occurs, inform medical personnel immediately. The metformin component can cause a rare but potentially fatal metabolic disorder called lactic acidosis; therefore, symptoms such as shortness of breath, muscle pain, severe fatigue, abdominal pain, and abnormal breathing should be monitored closely. Patients with impaired kidney function or conditions such as dehydration, severe infection, or heart failure should not take this medication, and it should be discontinued before and after procedures involving radiographic contrast agents. Women who are pregnant or breastfeeding, children under 18, and patients with severe liver impairment should also not take this medication. During treatment, irregular meals, excessive exercise, and interactions with other medications may increase the risk of hypoglycemia, so blood sugar levels should be checked frequently, and immediate action should be taken if symptoms occur. It is important to regularly monitor kidney function and conduct blood tests for abnormalities while taking this medication. Alcohol consumption may increase the risk of lactic acidosis, so alcohol should be avoided while on this medication. In the case of surgery, this medication should be stopped 48 hours prior to the procedure and only resumed after confirming normal kidney function upon recovery. Hypoglycemic symptoms include dizziness, headache, sweating, and trembling; if these symptoms occur, immediate intake of sugar is necessary. This medication may cause side effects such as arthralgia or skin conditions in some patients; if adverse symptoms persist, consult a doctor. Finally, this medication may increase the risk of hypoglycemia when used with other antidiabetic medications, so it is crucial to inform healthcare providers about any other drugs being taken.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 20 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • arthralgia with severe and disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • constipation
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a well-sealed container to prevent air ingress, and it is safest to keep it at room temperature between 1 to 30 degrees Celsius. This storage method helps maintain the effectiveness of the medication and prevents deterioration.

Appearance and packaging

Appearance

Bright blue, oval-shaped extended-release film-coated tablets that are convex on both sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.